Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biotechnology
Bispecific antibodies are artificial proteins that contain two different antigen-binding sites, allowing them to bind to two different types of antigens at the same time.1 As a result, bispecific antibodies can target several molecules, which potentially provides an advantage over utilizing combination therapies or mixtures of various antibodies, writes Dr Nicola Davies in her exclusive blog for The Pharma Letter. 8 July 2019
Biotechnology
East Coast, USA-based biotech Skyhawk Therapeutics has announced the expansion of an existing collaboration with Biogen, and a new research deal with New Jersey’s Merck & Co. 8 July 2019
Biotechnology
France’s Pierre Fabre and USA-based development partner Array BioPharma have announced positive interim analysis results from the Phase III BEACON CRC trial. 8 July 2019
Biotechnology
Evotec today announced the formation of Breakpoint Therapeutics GmbH, a spin-off company focusing on the development of the German biotech firm's DNA damage response (DDR) portfolio, comprising discovery-stage assets and drug targets that promise broad therapeutic application in a variety of cancers. 8 July 2019
Biotechnology
Privately-held German biotech firm Immatics Biotechnologies today announced that Harpreet Singh has been appointed the company’s chief executive (CEO). 8 July 2019
Biotechnology
A targeted drug has been accepted for routine use on the National Health Service (NHS) in England for some adults with untreated, advanced lung cancer. But another precision drug, for the same group of patients, has been rejected due to questions over its cost-effectiveness, noted that charity Cancer Research UK. 8 July 2019
Biotechnology
Global cell and gene therapy lobby group The Alliance for Regenerative Medicine (ARM) has published a new report, highlighting key policy proposals to advance the sector. 8 July 2019
Biotechnology
Hutchison China MediTech, also known as Chi-Med, has recently announced positive data that key late-stage asset surufatinib met the primary endpoint of PFS in non-pancreatic tumors (NET) sat the Phase III interim analysis. 5 July 2019
Biotechnology
French biotech firm GamaMabs Pharma has announced positive clinical data from its Phase II study of murlentamab in metastatic colorectal cancer (mCRC), at the European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer, taking place in Barcelona, Spain. 5 July 2019
Biotechnology
Shares of US clinical-stage drug developer Unum Therapeutics tumbled as much as 23% after the company revealed that the Food and Drug Administration had placed a "clinical hold" on the Phase I trial of its cancer treatment ACTR087. 4 July 2019
Biotechnology
Alexion Pharmaceuticals’ shares edged up almost 1% to $134.66 in after-hours trading on Wednesday, following the US drugmaker’s announcement that the European Commission had approved its rare blood disease drug Ultomiris (ravulizumab). 4 July 2019
Biotechnology
British drugmaker GlaxoSmithKline has said it will kick off late stage development of its novel immunological candidate otilimab. 4 July 2019
Biotechnology
Nosopharm and German biotech firm Evotec have entered into a partnership aimed at advancing Nosopharm’s lead candidate, NOSO-502, to the clinical stage, as well as developing a second-generation Odilorhabdin drug candidate. 3 July 2019
Biotechnology
Minzhang Chen, chief executive of WuXi STA, provides an Expert View on the opening up of the world's second largest pharma market. 3 July 2019
Biotechnology
US biotech Gilead Sciences and Belgium-based partner Galapagos both saw their shares go up by close of trading yesterday, after Gilead provided an update about the investigational oral, selective JAK1 inhibitor, filgotinib. 3 July 2019
Biotechnology
Swedish biotech Lokon Pharma, currently developing LOAd703, a potent double-armed (TMZ-CD40L/4-1BBL) oncolytic adenovirus for solid tumors, has announced a collaboration with Swiss pharma giant, Roche. 3 July 2019
Biotechnology
The total spinal muscular atrophy (SMA) market was estimated to be worth $1.5 billion across the seven major markets (7MM: the USA, France, Germany, Italy, Spain, UK and Japan) in 2018. 3 July 2019
Biotechnology
Belgium’s Confo Therapeutics has signed a drug discovery deal with Dresden, Germany-based DyNAbind, focused on an undisclosed G-protein coupled receptor (GPCR). 3 July 2019
Biotechnology
US biotech Amicus Therapeutics has entered into a strategic manufacturing agreement with Paragon Gene Therapy, a unit of Catalent Biologics. 2 July 2019
Biotechnology
US biotech Incyte and China and USA-based Zai Lab have entered into a collaboration and license agreement for the development and commercialization of INCMGA0012, an investigational anti-PD-1 monoclonal antibody, in Greater China. 2 July 2019
All news
Biotechnology
AstraZeneca and Daiichi Sankyo’s breast cancer med Enhertu (trastuzumab deruxtecan) will be included in China’s state-run health insurance scheme from next year, boosting availability at the cost of reduced pricing. 29 November 2024
Biotechnology
Minghui Pharmaceutical has reported encouraging results from a Phase III trial of MH004 (tofacitinib etocomil) in mild to moderate atopic dermatitis (AD). 29 November 2024
Biotechnology
Allink Biotherapeutics, a Chinese start-up focused on bispecific antibody and antibody-drug conjugates (ADC), has raised $42 million in a financing round led by Lanchi Ventures. 29 November 2024
Biotechnology
China’s Innovent Biologics has announced that the updated 2024 National Reimbursement Drug List (NRDL) now includes Sintbilo (tafolecimab) injection, an anti-PCSK9 monoclonal antibody for the first time. The updated NRDL will be officially effective from January 1, 2025. 29 November 2024
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze